Aphria (TSX:APHA) Loses its Biggest Customer: Sell the Cannabis Stock?

News on Tuesday is that cannabis firm Aphria (TSX:APHA)(NYSE:APHA) has lost a major supply deal that could have materially benefited the company and its stock investors over the next five strong years, and the company could be liable to refund the customer and pay damages. What we know Aphria entered an initial five-year wholesale cannabis supply agreement with Emblem Corp…

Read More

Forget Canopy Growth (TSX:WEED): Why This Pot Stock Could Triple in Value!

Canopy Growth (TSX:WEED)(NYSE:CGC) has been on a rough ride this year, falling more than 45% in six months and falling to below $30 a share. While it’s likely attracted the attention of investors thinking that it could be a good buy, whether that’s the case is questionable. Let’s not forget that this is the company that is still looking for…

Read More

Should Hexo (TSX:HEXO) Investors Be Alarmed After the CFO’s Sudden Departure Just Weeks Before Earnings?

Last week, we learned that Hexo’s (TSX:HEXO)(NYSE:HEXO) recently hired CFO Michael Monahan was resigning, just months after taking the job back in May. What’s surprising is that he cited location — Hexo is based the Gatineau-Ottawa area — as one of the key reasons as to why he would be resigning from the position. While the reasons could very well…

Read More

2 Cannabis Stocks That Could Land a Game-Changing Partner in 2020

Last year, nearly every cannabis company was racing to find a big-time partner. Cronos Group, for example, secured a $1.8 billion deal with tobacco giant Altria Group. Cronos stock ran more than 100% on the news, rising to a peak market cap of $20 billion. Canopy Growth, meanwhile, locked down a $4 billion capital infusion from Constellation Brands, causing shares…

Read More

KALY – Kali-Extracts Developing OTC and Prescription CBD Treatments

Kali Extracts

DALLAS, Oct. 08, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company is pursuing the development of Over-The-Counter (OTC) and prescription CBD treatments. The company yesterday released an update on its latest Cannabis Extract Biopharmaceutical developments. The information from yesterday’s release to include the specifics on the…

Read More